Drugs / J147
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03838185 | Jan 2019 → Feb 2020 | Alzheimer disease | Abrexa Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07430917 | Apr 2026 → Mar 2028 expected | ischemic stroke | Abrexa Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | J147 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07430917 ↗ |
| Modality | Small molecule | — CHEMBL2387144 ↗ |
| Route | Oral | “Single oral dose of J147” NCT03838185 ↗ |